Amazon, JPM, Berkshire form independent health company

The corporate giants gave few details, but said the initial aim is to provide U.S. staff with "high-quality and transparent healthcare at a reasonable cost."

By Shannon Muchmore • Jan. 30, 2018

Sanofi snaps up Ablynx after underwhelming Novo bid

In its second deal this year, the French pharma paid $4.8 billion to build its portfolio in rare blood disorders, beating competitor Novo Nordisk to the punch.

By Lisa LaMotta • Jan. 29, 2018

Prescribed Reading: Art of the deal, pharma dines with Trump

Just a few weeks into the year, M&A showed signs of life. Meanwhile, pharma execs schmoozed in Davos and Q4 earnings were all about the art of the deal. 

By Lisa LaMotta • Jan. 26, 2018

Spark deals Novartis ex-US rights to gene therapy for $105M

Licensing out Luxturna to the Swiss pharma will allow Spark to focus on the U.S. market, while giving it additional financial firepower to support commercialization.

By Ned Pagliarulo • Jan. 25, 2018

Celgene's task: Turn its shiny new toys into growth drivers

Acquiring Juno and Impact put a few potential blockbusters in Celgene's pipeline. Now, investors want to know how the big biotech will follow through.

By Jacob Bell • Jan. 25, 2018

Life science M&A volume down 27% last year, PwC finds

Deal value for big pharma was down 56% to $26 billion in 2017.

By Meg Bryant • Jan. 25, 2018

Biogen: No M&A 'frenzy' coming

The drugmaker announced a tiny deal that left investors wanting more, yet CEO Vounatsos didn't tip his hand about potential takeovers.

By Lisa LaMotta • Jan. 25, 2018

Recent M&A: Good buys or just a stopgap?

A new slate of biotech deals has investors feeling both elated and a bit confused.

By Lisa LaMotta • Jan. 23, 2018

Idera, BioCryst to merge, fortifying their position in rare disease

With the rare disease landscape heating up, the two companies will meld their pipelines and management to find a better footing.

By Jacob Bell • Jan. 22, 2018

Sanofi beefs up pipeline with $11B Bioverativ buy

The French pharma is adding a hemophilia franchise and strengthening its rare disease portfolio in a much-needed acquisition. 

By Lisa LaMotta • Jan. 22, 2018

Celgene buys Juno for $9B, deepening bet on CAR-T

Acquiring Juno will pit Celgene against Novartis and fellow large-cap biotech Gilead in the rapidly emerging field of cell therapy.

By Ned Pagliarulo • Jan. 22, 2018

Prescribed Reading: Murmurs of M&A, backlash over CRLs

Celgene may make another acquisition, while the FDA Commissioner gets his first negative marks for reneging on a promise. 

By Lisa LaMotta • Jan. 19, 2018

US health systems set up generic non-profit

In a move to cut shortages and stem price hikes, four health systems and the VA are creating their own generic drug company.

By Suzanne Elvidge • Jan. 19, 2018

Sandoz taps Biocon for biosimilar deal

The companies will collaborate on copycat biologics for cancer and immunology. 

By Lisa LaMotta • Jan. 18, 2018

Report: Small deals aren't the answer to big pharma's woes

Drugmakers turned to less pricey — and less risky — M&A in 2017, but a new report outlines why such deals won't solve industry-wide issues.

By Jacob Bell • Jan. 18, 2018

Post-review, Aeterna Zentaris strikes commercialization deal

After a complicated year including a strategic review, Quebecois company Aeterna Zentaris inks a small deal to help it move forward. 

By Suzanne Elvidge • Jan. 18, 2018

Boehringer, hot on deals, adds another with Adimab collaboration

A new deal gives the German drugmaker access to antibodies against a range of targets.

By Suzanne Elvidge • Jan. 12, 2018

JPM18: No mega-deals for Lilly, Ricks says

A Lilly SVP for business development also updated BioPharma Dive on areas of focus. 

By Lisa LaMotta • Jan. 11, 2018

JPM18 Day 3: Valeant and Acorda make plans, promises of M&A

Attendees were a bit more pessimistic during the last full day of the J.P. Morgan Healthcare Conference, but a few biotech CEOs still brimmed with confidence.

By Ned Pagliarulo , Lisa LaMotta • Jan. 10, 2018

JPM18 Day 2: Roche on gene therapy, Aimmune nears key readout and outpatient CAR-T

No new billion-dollar deals were announced on the second day of the J.P. Morgan meeting. Yet investors appeared more optimistic, pushing biotech shares up.

By Ned Pagliarulo , Lisa LaMotta • Jan. 9, 2018

Teva, Alder ink migraine deal to avoid legal headache

Locked in a heated race to market, the companies agreed to exchange cash for a patent license so both could move forward.

By Jacob Bell • Jan. 9, 2018

JPM18: Alnylam and Sanofi reshuffle rare disease RNAi deal

The new agreement restores Alnylam's rights to its ATTR amyloidosis portfolio, as well as opens potential income streams.

By Suzanne Elvidge • Jan. 9, 2018

JPM18: Regeneron, Sanofi boost I/O investment

The closely knit pair upped their investment in their immuno-oncology candidate, extending a partnership.

By Lisa LaMotta • Jan. 8, 2018

Novo Nordisk puts $3B on the table for Ablynx

The Danish drugmaker's latest offer is 14% higher than its first, but Ablynx remains unimpressed.

By Jacob Bell • Jan. 8, 2018

Celgene aims to quell growth worries with $7B Impact deal

Buying Impact Biomedicines will give Celgene an NDA-ready blood disease drug to bolster a pipeline shaken by a recent setback.

By Ned Pagliarulo • Jan. 7, 2018